We had never come this far before.
All for efficiency
One of the biggest difficulties in oncology drug development is getting the active ingredients exactly where they need to be.
Countless drugs fail to pass the clinical phases, not because of lack of efficacy, but because they are lost along the way.
The new collection that we are about to make available to you brings three major innovations.
And the greatest of them all is a galenic designed so that the active ingredients reach the last frontier of what can be considered a cosmetic: the basal membrane and the papillary dermis.
Beyond that point, we would be talking about a drug.
It is right there where the cells are that will make the difference in the most difficult thing to recover: the firmness of the skin.
During the time leading up to the launch I will be telling you the details, including the new products that will be arriving that did not exist in the previous collection.
More details about...
Our R&D in oncology
Our proposed therapy is based on the use of a recombinant protein that stimulates the production of a specific leukocyte.
This leukocyte provokes an immune response on the tumor that prevents its growth.
The treatment is currently in advanced stages of clinical trials. We conducted this research with the BCCC of the Hospital Clínic de Barcelona.
Our hope is that the treatment we have been working on for 15 years will help reduce metastatic lesions in patients.